đź“• Make Better Decisions: Finding and Evaluating Generic and Branded Drug Market Entry Opportunities
New book based on 20 years providing business guidance to drug companies [Free Sample]  [Buy printed book from Amazon] [More Details] Make […]
General Biotechnology
General Biotechnology, Insights, Tips, Tricks, and Case Studies
How to Use Drug Sales Data to Refine Your Channel Strategy and Improve Your Portfolio Management
Historic drug sales data can help with market sizing. By examining sales trends over time you can gauge the attractiveness of the market entry. For patented drugs examining sales trends…
The post How to Use Drug Sales Data to Refine Your Channel Strate…
General Biotechnology, Guest content
Are Headlines of Medical Breakthroughs Overstating Actual Science and Research?
By Joshua Mansour, M.D. Patients should have as much access to information as possible. The more they know, the more
Are Headlines of Medical Breakthroughs Overstating Actual Science and Research? Read Post »
General Biotechnology, Guest content
New FDA Commissioner: What this means for Cancer Testing and Treatment
By Joshua Mansour, M.D. The head of the National Cancer Institute, Dr. Norman “Ned” Sharpless, will be temporarily appointed as acting
New FDA Commissioner: What this means for Cancer Testing and Treatment Read Post »
General Biotechnology
Telemedicine, Changing the Face of Healthcare
By Eddie Fatakhov, M.D. Advancements in technology are dramatically changing the world of medicine as we know it, and medical
General Biotechnology, Insights
Conclusions We Can Draw from Recent Successful Drug Launches
Recent successful drug launches indicate a trend toward more specialized, high-priced drugs that treat less-common medical conditions.
The post Conclusions We Can Draw from Recent Successful Drug Launches appeared first on DrugPatentWatch – Make Better…
Conclusions We Can Draw from Recent Successful Drug Launches Read Post »
General Biotechnology, Insights
Mark Cuban Unexpected Leader in Orphan Drug Development Reform
Businessman and investor Mark Cuban is probably best known as the owner of the Dallas Mavericks and as an investor on the reality television series Shark Tank. His business and…
The post Mark Cuban Unexpected Leader in Orphan Drug Development Reform ap…
Mark Cuban Unexpected Leader in Orphan Drug Development Reform Read Post »
General Biotechnology, Insights
How AI Is Already Changing Drug Development
The average time to market for a new drug is around 12 years, at a cost averaging $2.6 billion, according to 2014 research by Tufts University. And there’s no indication that…
The post How AI Is Already Changing Drug Development appeared first on DrugP…
General Biotechnology, Guest content, Insights
Business Continuity and Resiliency Planning for Biomedical and Research Organizations
By Nanette Moss, S.M., C.I.H., Senior Scientist and Project Executive with Environmental Health & Engineering, Inc. What is business continuity planning and why it is important? Emergencies may be infrequent…
The post Business Continuity and Resiliency…
Business Continuity and Resiliency Planning for Biomedical and Research Organizations Read Post »
General Biotechnology, Insights
Key Findings from GAO Report on Orphan Drug Approval Modernization
In November 2018, the Government Accountability Office (GAO) released a report titled “FDA Could Improve Designation Review Consistency; Rare Disease Drug Development Challenges Continue.” It follows up on the FDA’s Orphan…
The post Key Findings from G…
Key Findings from GAO Report on Orphan Drug Approval Modernization Read Post »